Results

1–10 of 162 results for Retinal Vascular Disease

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
Reducing Time to Treatment of Retinal Artery Occlusions Using a Remote Diagnostic Protocol
Gareth Lema, MD, PhD
Annual Meeting Talks
2024
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Annual Meeting Talks
2024
Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage
Alan J. Franklin, MD, PhD
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Risk of Retinal Vein and Artery Occlusions
Aleksandra V. Rachitskaya, MD, FASRS
Updates from the Field
2025
The Associated Risk Over Time of Cerebrovascular and Cardiovascular Events in Branch and Central Retinal Artery Occlusions
Robin A Vora, MD
Updates from the Field
2025
Suprachoroidal Hemorrhage
Retina Image Bank: Images of the Week
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024